Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Abstract Background Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the development of BACE1 inhibitors, we report detailed safety fin...

Full description

Bibliographic Details
Main Authors: Michael F. Egan, Yuki Mukai, Tiffini Voss, James Kost, Julie Stone, Christine Furtek, Erin Mahoney, Jeffrey L. Cummings, Pierre N. Tariot, Paul S. Aisen, Bruno Vellas, Christopher Lines, David Michelson
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Alzheimer’s Research & Therapy
Subjects:
Verubecestat
BACE inhibitor
Amyloid
Alzheimer’s disease
Clinical trial
Safety
Online Access:http://link.springer.com/article/10.1186/s13195-019-0520-1

Internet

http://link.springer.com/article/10.1186/s13195-019-0520-1

Similar Items